Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Voyageur Pharmaceuticals partners with Rain Cage to develop nanocarbon-based radiology drugs By: TheNewswire.com - RSS (Media) May 24, 2023 at 14:22 PM EDT Voyageur Pharmaceuticals CEO Brent Willis join's Proactive's Natalie Stoberman to share a significant licensing agreement with Rain Cage Carbon to develop nanocarbon-based contrast drugs for medical imaging. Willis says the partnership aims to develop new contrast agents for the radiology drug market while also making Voyageur the first carbon-neutral pharmaceutical company in the industry. He explains that Rain Cage Carbon's innovative technology allows Voyageur to extract carbon dioxide and other emissions, generating high-grade carbon for various applications. By leveraging this technology, Willis says Voyageur plans to create safer and more effective drugs using carbon 60 molecules. Contact DetailsProactive Investors+1 604-688-8158na-editorial@proactiveinvestors.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Voyageur Pharmaceuticals partners with Rain Cage to develop nanocarbon-based radiology drugs By: TheNewswire.com - RSS (Media) May 24, 2023 at 14:22 PM EDT Voyageur Pharmaceuticals CEO Brent Willis join's Proactive's Natalie Stoberman to share a significant licensing agreement with Rain Cage Carbon to develop nanocarbon-based contrast drugs for medical imaging. Willis says the partnership aims to develop new contrast agents for the radiology drug market while also making Voyageur the first carbon-neutral pharmaceutical company in the industry. He explains that Rain Cage Carbon's innovative technology allows Voyageur to extract carbon dioxide and other emissions, generating high-grade carbon for various applications. By leveraging this technology, Willis says Voyageur plans to create safer and more effective drugs using carbon 60 molecules. Contact DetailsProactive Investors+1 604-688-8158na-editorial@proactiveinvestors.com